It's a tremendous sign of success for the vaccine, but it's also a personalized vaccine. That means it can't simply be produced at significant scale, at least not easily, anyway. It requires a custom-manufacturing process which can span six weeks.

Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial. When stock prices and headlines point in opposite directions across the sector,

Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large Phase 3 trial, proving they can deliver the goods.

One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third carries the fate of millions of retirees.

Shares of Moderna have comfortably outperformed the broader market over the past year, surging 885% compared to the S&P 500 Index's ($SPX) 8.2% surge. Moreover, in 2026, the stock has risen by nearly 712.7%, also outpacing the SPX's 7.4% gain.

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however, be too late to play the forces behind its rise.

Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's vaccine portfolio, drug pipeline outlook, and more.

Investors are thrilled with the results and the money that intismeran may bring in for Moderna in the future. CEO Stéphane Bancel is excited about the possibility for the treatment to also go beyond just melanoma, stating that, "We believe it will work everywhere Keytruda works."